SCHEMBL1883484

SCHEMBL1883484

O=Cc1cc2cccc(Cc3ccccc3)c2nc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPT P10636 4/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
NPSR1 Q6W5P4 3/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1881135 0.84 ALDH1A1 (0.45) DRD4DRD3L3MBTL1MAPTKDM4E
SCHEMBL1890156 0.78 DRD4 (0.51) DRD4DRD3L3MBTL1KDM4EALDH1A1
SCHEMBL458716 0.77 KDR (0.54) DRD4DRD3L3MBTL1MAPTKDM4E
SCHEMBL29683769 0.77 ALDH1A1 (0.46) MAPTKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL5116 0.77 ALDH1A1 (0.46) MAPTKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL19331488 0.74 ALDH1A1 (0.44) MAPTKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL719667 0.74 ALDH1A1 (0.44) MAPTKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL6808136 0.73 CYP11B1 (0.45) ALDH1A1CYP1A2CYP2D6CYP2C19LMNA
SCHEMBL20291568 0.72 ALDH1A1 (0.47) DRD4DRD3L3MBTL1MAPTKDM4E
SCHEMBL4181276 0.71 PDE3B (0.46) L3MBTL1MAPTKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE DRD4 3720/4885DRD3 2440/4885L3MBTL1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.